Abstract
Here, we confirmed that stable expression of B-cell lymphoma-xL (Bcl-xL) in N18TG neuroglioma cells could suppress c-Jun N-terminal protein kinase (JNK) activation, nuclear fragmentation, and cell death caused by etoposide treatment. Moreover, additional overexpression of JNK1 led to partially antagonize the antiapoptotic environment attained by Bcl-xL, implying that JNK1-involved pathway may play a role in down-regulation of the antiapoptotic effect of Bcl-xL. However, the antagonistic effect of JNK1 on the antiapoptotic action of Bcl-xL was significantly weaker than that on the action of Bcl-2. Interestingly, we found that overexpression of JNK1 led to increase of Bcl-xL expression. Thus, these results suggest that Bcl-xL and Bcl-2 may induce its antiapoptotic effect in a different mechanism, provoking the possibility of involvement of JNK1-involved pathway in Bcl-xL expression.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents, Phytogenic / pharmacology
-
Apoptosis Regulatory Proteins / physiology*
-
Blotting, Western
-
Brain Neoplasms / metabolism*
-
Cell Death / drug effects
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
DNA Fragmentation / drug effects
-
Enzyme Activation / drug effects
-
Etoposide / pharmacology
-
Glioma / metabolism*
-
Humans
-
Mitogen-Activated Protein Kinase 8 / biosynthesis*
-
Mitogen-Activated Protein Kinase 8 / genetics
-
Proto-Oncogene Proteins c-bcl-2 / biosynthesis*
-
Proto-Oncogene Proteins c-bcl-2 / genetics
-
Reverse Transcriptase Polymerase Chain Reaction
-
Signal Transduction / drug effects
-
Transfection
-
bcl-X Protein / biosynthesis*
-
bcl-X Protein / genetics
Substances
-
Antineoplastic Agents, Phytogenic
-
Apoptosis Regulatory Proteins
-
Proto-Oncogene Proteins c-bcl-2
-
bcl-X Protein
-
Etoposide
-
Mitogen-Activated Protein Kinase 8